Monkasta (Montelukast)

Montelukast, the active ingredient in Monkasta, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed to manage chronic asthma and allergic rhinitis in adults and children as part of maintenance therapy. The medication is formulated to ensure consistent bioavailability and is approved for use in the European Union.

GNH USA supplies Monkasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable, on‑time delivery across multiple markets.

Montelukast acts on leukotriene pathways to control inflammatory airway conditions.

Asthma (maintenance therapy): reduces frequency of bronchospasm episodes and improves overall lung function. Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal allergies. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate head pain. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: persistent dry cough. - Nausea: feeling of queasiness, sometimes with vomiting.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, angioedema, or anaphylaxis. - Liver enzyme elevation: increased transaminases indicating hepatic stress. - Neuropsychiatric events: mood changes, depression, suicidal thoughts. - Severe cutaneous adverse reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Montelukast, clinicians should consider several safety and handling precautions. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Liver impairment: dose adjustment may be required; monitor hepatic function. - Concomitant enzyme inducers: drugs such as phenobarbital may reduce Montelukast exposure. - Neuropsychiatric monitoring: observe patients for mood alterations, depression or suicidal ideation. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Montelukast can interact with other medicines, affecting its plasma levels or therapeutic effect.

Major Interactions (Avoid): - Ritonavir: potent CYP3A4 inhibitor may markedly increase Montelukast concentrations. - Phenobarbital, carbamazepine, phenytoin: strong CYP inducers can lower drug exposure and reduce efficacy. - Fluconazole: moderate CYP3A4 inhibition may raise systemic levels.

Moderate Interactions (Monitor Closely): - Warfarin: Montelukast may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: possible increase in plasma concentration, monitor for toxicity.